Back to Journals » OncoTargets and Therapy » Volume 10

Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review

Authors He W, Zou C, Tian ZK, Tan WY, Shen WX, Chen JH, Liu LP, Xu RL

Received 13 September 2016

Accepted for publication 29 October 2016

Published 20 December 2016 Volume 2017:10 Pages 67—72

DOI https://doi.org/10.2147/OTT.S122238

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ashok Kumar Pandurangan

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly

Wan He,1,* Chang Zou,2,* Zhongkai Tian,1 Wenyong Tan,1 Weixi Shen,3 Jinghua Chen,1 Liping Liu,4 Ruilian Xu1

1Department of Oncology, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, China; 2Clinical Medical Research Center, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, China; 3Department of Oncology, Shenzhen Hospital of Southern Medical University, Shenzhen, China; 4Department of Hepatobiliary and Pancreatic Surgery, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, China

*These authors contributed equally to this work

Abstract: Patients with stage IV nasopharyngeal carcinoma (NPC) have a poor prognosis, even with effective chemotherapy. Target agents combined with chemotherapy may improve NPC patients’ outcome. The case of a patient with NPC, who was treated by adding bevacizumab to chemotherapy after disease progression using first-line chemotherapy, is reported. Recently published literature about effects of combining bevacizumab with standard chemotherapy in NPC cell lines or patients are also reviewed and discussed. Consistent with a few preclinical trials and Phase II clinical trials, bevacizumab may reverse the drug resistance to chemotherapy, and its toxic side effects are well tolerated.

Keywords: nasopharyngeal carcinoma, bevacizumab, drug resistance, combination therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]